Glucocorticoids and insulin resistance: old hormones, new targets.

Insulin resistance has been proposed as a mediator of the association between risk factors for cardiovascular disease in the population. The clinical syndrome of glucocorticoid excess (Cushing's syndrome) is associated with glucose intolerance, obesity and hypertension. By opposing the actions of insulin, glucocorticoids could contribute to insulin resistance and its association with other cardiovascular risk factors. In this review, we describe briefly the known mechanisms of insulin resistance and highlight the potential mechanisms for the effect of glucocorticoids. We then discuss factors which modulate the influence of glucocorticoids on insulin sensitivity; this highlights a novel therapeutic strategy to manipulate glucocorticoid action which may prove to be a useful tool in treating subjects with insulin resistance. Finally, we describe evidence from human studies that glucocorticoids make an important contribution to the pathophysiology of insulin resistance in the population.

[1]  B. Walker,et al.  11 beta-hydroxysteroid dehydrogenase type 1 is a predominant 11 beta-reductase in the intact perfused rat liver. , 2000, The Journal of endocrinology.

[2]  A Mari,et al.  How to measure insulin sensitivity , 1998, Journal of hypertension.

[3]  P. Björntorp,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Stress-Related Cortisol Secretion in Men: Relationships with Abdominal Obesity and Endocrine, Metabolic and , 2022 .

[4]  J. Connell,et al.  Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. , 1998, The Journal of clinical endocrinology and metabolism.

[5]  C. Östenson,et al.  Increased glucocorticoid sensitivity in islet beta-cells: effects on glucose 6-phosphatase, glucose cycling and insulin release , 1998, Diabetologia.

[6]  M. Nyirenda,et al.  Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. , 1998, The Journal of clinical investigation.

[7]  B. Walker,et al.  Obesity and gender influence cortisol secretion and metabolism in man. , 1998, The Journal of clinical endocrinology and metabolism.

[8]  D. Webb,et al.  Increased glucocorticoid activity in men with cardiovascular risk factors. , 1998, Hypertension.

[9]  Jeppe Sturis,et al.  Temporal Profiles and Clinical Significance of Pulsatile Insulin Secretion , 1998, Hormone Research in Paediatrics.

[10]  J. Seckl,et al.  11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Veglio,et al.  Impaired cortisol binding to glucocorticoid receptors in hypertensive patients. , 1997, Hypertension.

[12]  S. Jacob,et al.  Insulin Resistance, Hyperinsulinemia, and Blood Pressure Role of Age and Obesity , 1997 .

[13]  C. Östenson,et al.  Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. , 1997, The Journal of clinical investigation.

[14]  S. O’Rahilly,et al.  Molecular mechanisms of inherited insulin resistance. , 1997, QJM : monthly journal of the Association of Physicians.

[15]  S. Woods,et al.  Adrenalectomy Increases Sensitivity to Central Insulin , 1997, Physiology & Behavior.

[16]  E. Ferrannini,et al.  Renal effects of insulin in man. , 1997, Journal of nephrology.

[17]  E. Araki,et al.  Impact of Natural IRS-1 Mutations on Insulin Signals: Mutations of IRS-1 in the PTB Domain and Near SH2 Protein Binding Sites Result in Impaired Function at Different Steps of IRS-1 Signaling , 1997, Diabetes.

[18]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[19]  P. Stewart,et al.  Does central obesity reflect “Cushing's disease of the omentum”? , 1997, The Lancet.

[20]  C. Kahn,et al.  Development of a Novel Polygenic Model of NIDDM in Mice Heterozygous for IR and IRS-1 Null Alleles , 1997, Cell.

[21]  P. Gilon,et al.  Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. , 1997, The Journal of clinical investigation.

[22]  G. Dimitriadis,et al.  Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. , 1997, The Biochemical journal.

[23]  G. Boden.  Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[24]  J. Seckl,et al.  Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. , 1996, Neuroendocrinology.

[25]  H. Sipilä,et al.  Evidence for Dissociation of Insulin Stimulation of Blood Flow and Glucose Uptake in Human Skeletal Muscle: Studies Using [15O]H2O, [18F]fluoro-2-deoxy-D-glucose, and Positron Emission Tomography , 1996, Diabetes.

[26]  J. Seckl,et al.  Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 b -hydroxysteroid dehydrogenase inhibitor carbenoxolone , 1996, Diabetologia.

[27]  G. Vallega,et al.  In vivo effects of dexamethasone and sucrose on glucose transport (GLUT-4) protein tissue distribution. , 1996, The American journal of physiology.

[28]  S. O’Rahilly,et al.  Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. , 1996, The Journal of clinical endocrinology and metabolism.

[29]  D. Finegood,et al.  The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. , 1996, The Journal of clinical endocrinology and metabolism.

[30]  P. Björntorp,et al.  Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. , 1996, Obesity research.

[31]  R. Stolk,et al.  Gender differences in the associations between cortisol and insulin in healthy subjects. , 1996, The Journal of endocrinology.

[32]  J. Filipovský,et al.  The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men , 1996, Journal of hypertension.

[33]  B. Walker,et al.  Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. , 1996, Hypertension.

[34]  C. Edwards,et al.  11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. , 1995, Endocrinology.

[35]  D. Webb,et al.  Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. , 1995, The Journal of clinical endocrinology and metabolism.

[36]  G. Boden,et al.  Effects of a 48-h Fat Infusion on Insulin Secretion and Glucose Utilization , 1995, Diabetes.

[37]  T. Mune,et al.  Human hypertension caused by mutations in the kidney isozyme of 11β–hydroxysteroid dehydrogenase , 1995, Nature Genetics.

[38]  A. Baron,et al.  Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. , 1995, The Journal of clinical investigation.

[39]  M. Itoh,et al.  Dexamethasone-induced changes in glucose transporter 4 in rat heart muscle, skeletal muscle and adipocytes. , 1995, European journal of endocrinology.

[40]  S. Weinstein,et al.  Glucocorticoid-Induced Insulin Resistance: Dexamethasone Inhibits the Activation of Glucose Transport in Rat Skeletal Muscle by Both Insulin- and Non-Insulin-Related Stimuli , 1995, Diabetes.

[41]  I. Robinson,et al.  Sexual dimorphism of hepatic 11 beta-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. , 1994, The Journal of endocrinology.

[42]  Z. Krozowski,et al.  Cloning and tissue distribution of the human 1 lβ-hydroxysteroid dehydrogenase type 2 enzyme , 1994, Molecular and Cellular Endocrinology.

[43]  T. Mune,et al.  NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. , 1994, The Journal of biological chemistry.

[44]  C. Edwards,et al.  'Liver-type' 11 beta-hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS-7 cells. , 1994, Journal of molecular endocrinology.

[45]  A. Quyyumi,et al.  Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. , 1994, Journal of the American College of Cardiology.

[46]  F. Féry.  Role of hepatic glucose production and glucose uptake in the pathogenesis of fasting hyperglycemia in type 2 diabetes: normalization of glucose kinetics by short-term fasting. , 1994, The Journal of clinical endocrinology and metabolism.

[47]  R. Clayton,et al.  Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. , 1994, The New England journal of medicine.

[48]  Marie Martin,et al.  In vivo effect of free fatty acids on the specific binding of glucocorticosteroids to corticosteroid binding globulin and liver receptors in immature rats , 1994, Steroids.

[49]  R. Rizza,et al.  Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. , 1993, The Journal of clinical investigation.

[50]  A. Atkinson,et al.  The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action. , 1993, The Journal of clinical endocrinology and metabolism.

[51]  H. Adlercreutz,et al.  Altered adrenocorticotropin and Cortisol secretion in abdominal obesity: implications for the insulin resistance syndrome , 1993, Journal of internal medicine.

[52]  M. Dallman,et al.  Feast and Famine: Critical Role of Glucocorticoids with Insulin in Daily Energy Flow , 1993, Frontiers in Neuroendocrinology.

[53]  R. Pasquali,et al.  The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. , 1993, The Journal of clinical endocrinology and metabolism.

[54]  B. Walker,et al.  Deficient inactivation of cortisol by 11β‐hydroxysteroid dehydrogenase in essential hypertension , 1993, Clinical endocrinology.

[55]  H. Elayan,et al.  Glucocorticoid induction of epinephrine synthesizing enzyme in rat skeletal muscle and insulin resistance. , 1993, The Journal of clinical investigation.

[56]  C. Lau,et al.  Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients , 1993, The Lancet.

[57]  F. Giorgino,et al.  Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. , 1993, The Journal of clinical investigation.

[58]  A. Quyyumi,et al.  Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. , 1993, Journal of the American College of Cardiology.

[59]  R. Benediktsson,et al.  Glucocorticoid exposure in utero: new model for adult hypertension , 1993, The Lancet.

[60]  B. Walker,et al.  Mineralocorticoid excess and inhibition of 11 β‐hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome , 1992, Clinical endocrinology.

[61]  G. Hitman,et al.  An association between a Bc1I restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsulinaemia in obese women. , 1992, Journal of molecular endocrinology.

[62]  P. Björntorp,et al.  Cortisol secretion in relation to body fat distribution in obese premenopausal women. , 1992, Metabolism: clinical and experimental.

[63]  L. Groop,et al.  Reversal of steroid-induced insulin resistance by a nicotinic-acid derivative in man. , 1992, Metabolism: clinical and experimental.

[64]  G. Watt,et al.  Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure. , 1992, Journal of hypertension.

[65]  R. Simsolo,et al.  The regulation of lipoprotein lipase gene expression by dexamethasone in isolated rat adipocytes. , 1992, Endocrinology.

[66]  P. Stewart,et al.  Novel aspects of hormone action: Intracellular ligand supply and its control by a series of tissue specific enzymes , 1992, Molecular and Cellular Endocrinology.

[67]  A. Vanet,et al.  Modulatory effects of unsaturated fatty acids on the binding of glucocorticoids to rat liver glucocorticoid receptors. , 1991, Endocrinology.

[68]  P. Björntorp.  Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? , 1991, Journal of internal medicine.

[69]  D. York,et al.  Central glucocorticoid regulation of parasympathetic drive to pancreatic B-cells in the obese fa/fa rat. , 1991, International journal of obesity.

[70]  P. Siiteri,et al.  Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action. , 1991, The Journal of clinical endocrinology and metabolism.

[71]  M. Vranic,et al.  Dexamethasone increases glucose cycling, but not glucose production, in healthy subjects. , 1990, The American journal of physiology.

[72]  C. Edwards,et al.  5 α-reductase activity in polycystic ovary syndrome , 1990, The Lancet.

[73]  P. White,et al.  Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. , 1989, The Journal of biological chemistry.

[74]  J Golding,et al.  Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. , 1989, BMJ.

[75]  J. Funder,et al.  Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. , 1988, Science.

[76]  D. Giannella‐Neto,et al.  GLUCOCORTICOIDS AND GLUCOSE METABOLISM: HEPATIC GLUCOSE PRODUCTION IN UNTREATED ADDISONIAN PATIENTS AND ON TWO DIFFERENT LEVELS OF GLUCOCORTICOID ADMINISTRATION , 1988, Clinical endocrinology.

[77]  P. Stewart,et al.  MINERALOCORTICOID ACTIVITY OF LIQUORICE: 11-BETA-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY COMES OF AGE , 1987, The Lancet.

[78]  G. Reaven,et al.  A ROLE FOR INSULIN IN THE AETIOLOGY AND COURSE OF HYPERTENSION? , 1987, The Lancet.

[79]  D. Housman,et al.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. , 1987, Science.

[80]  J. Funder,et al.  Mineralocorticoid specificity of renal type I receptors: in vivo binding studies. , 1987, The American journal of physiology.

[81]  M. Cassader,et al.  An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. , 1983, The Journal of clinical investigation.

[82]  J. Funder,et al.  Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[83]  D. Linch,et al.  CUSHING'S SYNDROME—KILLING DISEASE: DISCRIMINATORY VALUE OF SIGNS AND SYMPTOMS AIDING EARLY DIAGNOSIS , 1982, The Lancet.

[84]  I. G. Fantus,et al.  The effect of glucocorticoids on the insulin receptor: an in vivo and in vitro study. , 1981, The Journal of clinical endocrinology and metabolism.

[85]  I. Testa,et al.  Effect of dexamethasone and cortisone on insulin receptors in normal human male. , 1980, The Journal of clinical endocrinology and metabolism.

[86]  C. Kahn,et al.  Alterations in insulin binding induced by changes in vivo in the levels of glucocorticoids and growth hormone. , 1978, Endocrinology.

[87]  O. Owen,et al.  Metabolic effects of exogenous glucocorticoids in fasted man. , 1973, The Journal of clinical investigation.

[88]  B. Walker,et al.  11 -Hydroxysteroid dehydrogenase type 1 is a predominant 11 -reductase in the intact perfused rat liver , 2000 .

[89]  M. Nyirenda,et al.  Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: possible evidence for a role of hepatic 11beta-hydroxysteroid dehydrogenase type 1. , 1999, The Journal of endocrinology.

[90]  M. Hewison,et al.  Regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. , 1998, The Journal of endocrinology.

[91]  K. E. Chapman,et al.  11Beta-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. , 1998, The Journal of steroid biochemistry and molecular biology.

[92]  R. Hanson,et al.  Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. , 1997, Annual review of biochemistry.

[93]  N. Glorioso,et al.  Evidence of Coexisting Changes in 11β-Hydroxysteroid Dehydrogenase and 5β-Reductase Activity in Subjects With Untreated Essential Hypertension , 1995 .

[94]  C. Edwards,et al.  Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man. , 1990, Clinical science.

[95]  C. Edwards,et al.  Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. , 1988, Lancet.

[96]  A. Wallace,et al.  MINERALOCORTICOID ACTIVITY OF LIQUORICE: 11Β-HYDROXYSTEROID DEHYDROGENASE DEFFICIENCY COMES OF AGE , 1987 .

[97]  L. Mandarino,et al.  Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. , 1982, The Journal of clinical endocrinology and metabolism.

[98]  H. Beck-Nielsen,et al.  Prednisone increases the number of insulin receptors on monocytes from normal subjects. , 1980, The Journal of clinical endocrinology and metabolism.